Clinical Trials Directory

Trials / Sponsors / Sinovac Life Sciences Co., Ltd.

Sinovac Life Sciences Co., Ltd.

Industry · 22 registered clinical trials — 6 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingPhase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
Meningococcal Meningitis
Phase 12026-01-21
RecruitingClinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years
Pneumococcal Infectious Disease
Phase 22025-11-25
RecruitingClinical Trial of PCV24 in Infants Aged 2-23 Months
Pneumococcal Infectious Disease
Phase 12025-05-08
Not Yet RecruitingSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participant
Tetanus
Phase 1 / Phase 22025-04-01
RecruitingPhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
Rotavirus Gastroenteritis
Phase 22025-01-20
RecruitingClinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
Pneumococcal Infectious Disease
Phase 32024-10-23
CompletedClinical Trial of PCV24 in Children Aged 2-17 Years
Pneumococcal Infectious Disease
Phase 12024-09-07
CompletedClinical Trial of PCV24 in Adults
Pneumococcal Infectious Disease
Phase 12024-06-21
CompletedThe Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)
Rotavirus Gastroenteritis
Phase 12024-03-27
CompletedSafety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
Tetanus
Phase 32023-09-01
UnknownSA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients
Infection of Upper Respiratory Tract Caused by 2019-nCoV
Phase 22023-08-31
UnknownSA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19
COVID-19
Phase 12023-06-15
UnknownSA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People
COVID-19
Phase 12023-05-31
CompletedSafety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Pneumococcal Infections
Phase 12023-01-03
UnknownEfficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People
COVID-19
N/A2022-11-26
UnknownEfficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
COVID-19
N/A2022-10-30
UnknownImmunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-
COVID-19
Phase 42022-04-19
CompletedImmunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly
COVID-19
Phase 42021-12-06
CompletedSafety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inac
COVID-19
Phase 42021-10-20
CompletedSafety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents
COVID-19
Phase 42021-07-24
CompletedSafety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
COVID-19
Phase 22021-05-03
CompletedSafety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)
COVID-19
Phase 1 / Phase 22020-05-22